Brett K Beaulieu-Jones, Francesca Frau, Sylvie Bozzi, Karen J Chandross, M Judith Peterschmitt, Caroline Cohen, Catherine Coulovrat, Dinesh Kumar, Mark J Kruger, Scott L Lipnick, Lane Fitzsimmons, Isaac S Kohane, Clemens R Scherzer
Characterization of Parkinson's disease (PD) progression using real-world evidence could guide clinical trial design and identify subpopulations. Efforts to curate research populations, the increasing availability of real-world data, and advances in natural language processing, particularly large language models, allow for a more granular comparison of populations than previously possible. This study includes two research populations and two real-world data-derived (RWD) populations. The research populations are the Harvard Biomarkers Study (HBS, N = 935), a longitudinal biomarkers cohort study with in-person structured study visits; and Fox Insights (N = 36,660), an online self-survey-based research study of the Michael J...
March 13, 2024: NPJ Parkinson's Disease